Compliance with the guidelines on recommended immunization schedule in patients with inflammatory bowel disease: implications on public health policies.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
19 May 2020
Historique:
received: 14 01 2020
accepted: 05 05 2020
entrez: 21 5 2020
pubmed: 21 5 2020
medline: 10 10 2020
Statut: epublish

Résumé

Patients with inflammatory bowel disease (IBD) have a higher risk of developing opportunistic infections due to either the disease itself or to treatment with immunosuppressants. This risk can be reduced through vaccination. The aim of this study was to determine the prevalence of compliance with the guidelines on recommended immunization schedule in patients with IBD in the health district of Lleida, Spain. Descriptive, cross-sectional, retrospective study of data at December 31, 2016. The reference population was formed by adults with a clinical diagnosis of IBD. The dependent variable was "compliance with the guidelines on recommended immunization schedule". Variables were sex, age, residence, diagnosis, vaccination against measles, mumps, rubella, varicella, tetanus-diphtheria, influenza, pneumococcus, meningococcus C, hepatitis B, and hepatitis A. Data were obtained from electronic medical records. For the data analysis, mean (standard deviation), prevalence with 95% confidence intervals, χ Compliance did not exceed 65% for any of vaccines analysed in the 1722 studied patients with ulcerative colitis or Crohn's disease. Significant differences across age groups were found in compliance for measles, mumps, rubella, varicella, tetanus, diphtheria and influenza in both ulcerative colitis and Crohn's disease and for meningococcus C and hepatitis A exclusively in ulcerative colitis. Compliance in patients with IBD is low. Thus, prevention of immunopreventable diseases or their complications is not maximized in this kind of patients. Greater awareness of how vaccines can reduce the risk of vaccine-preventable infections is needed among both patients and healthcare professionals.

Sections du résumé

BACKGROUND BACKGROUND
Patients with inflammatory bowel disease (IBD) have a higher risk of developing opportunistic infections due to either the disease itself or to treatment with immunosuppressants. This risk can be reduced through vaccination. The aim of this study was to determine the prevalence of compliance with the guidelines on recommended immunization schedule in patients with IBD in the health district of Lleida, Spain.
METHODS METHODS
Descriptive, cross-sectional, retrospective study of data at December 31, 2016. The reference population was formed by adults with a clinical diagnosis of IBD. The dependent variable was "compliance with the guidelines on recommended immunization schedule". Variables were sex, age, residence, diagnosis, vaccination against measles, mumps, rubella, varicella, tetanus-diphtheria, influenza, pneumococcus, meningococcus C, hepatitis B, and hepatitis A. Data were obtained from electronic medical records. For the data analysis, mean (standard deviation), prevalence with 95% confidence intervals, χ
RESULTS RESULTS
Compliance did not exceed 65% for any of vaccines analysed in the 1722 studied patients with ulcerative colitis or Crohn's disease. Significant differences across age groups were found in compliance for measles, mumps, rubella, varicella, tetanus, diphtheria and influenza in both ulcerative colitis and Crohn's disease and for meningococcus C and hepatitis A exclusively in ulcerative colitis.
CONCLUSIONS CONCLUSIONS
Compliance in patients with IBD is low. Thus, prevention of immunopreventable diseases or their complications is not maximized in this kind of patients. Greater awareness of how vaccines can reduce the risk of vaccine-preventable infections is needed among both patients and healthcare professionals.

Identifiants

pubmed: 32429900
doi: 10.1186/s12889-020-08850-y
pii: 10.1186/s12889-020-08850-y
pmc: PMC7236120
doi:

Substances chimiques

Immunosuppressive Agents 0
Vaccines 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

713

Références

Gastroenterol Hepatol. 2003 Jan;26(1):19-22
pubmed: 12525323
J Crohns Colitis. 2019 Jul 25;13(7):828-837
pubmed: 30668662
Hum Vaccin Immunother. 2013 Sep;9(9):1918-25
pubmed: 23793571
Am J Gastroenterol. 2010 Jun;105(6):1231-8
pubmed: 20104218
Medicine (Baltimore). 2015 Jun;94(22):e940
pubmed: 26039133
Inflamm Bowel Dis. 2009 Sep;15(9):1410-6
pubmed: 19462435
Aten Primaria. 2018 Nov;50(9):553-559
pubmed: 29373143
Rev Esp Salud Publica. 2019 Mar 25;93:
pubmed: 30907380
JAMA. 1978 Jan 2;239(1):45-6
pubmed: 579232
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):205-17
pubmed: 25732745
Med Care. 2007 Jun;45(6):521-8
pubmed: 17515779
Gut. 2008 Apr;57(4):549-58
pubmed: 18178610
Rev Esp Enferm Dig. 2013 Feb;105(2):93-102
pubmed: 23659508
Clin Gastroenterol Hepatol. 2007 Jul;5(7):851-6
pubmed: 17544875
Rev Gastroenterol Mex. 2019 Jan - Mar;84(1):11-17
pubmed: 29605092
Inflamm Bowel Dis. 2012 Jun;18(6):1042-7
pubmed: 21674732
World J Gastroenterol. 2015 Oct 28;21(40):11273-81
pubmed: 26527572
Gastroenterology. 2008 Apr;134(4):929-36
pubmed: 18294633
Dig Dis Sci. 2012 Apr;57(4):1039-44
pubmed: 22147248
J Crohns Colitis. 2014 Jun;8(6):443-68
pubmed: 24613021
Dig Dis Sci. 2018 Jan;63(1):4-6
pubmed: 29127607
Inflamm Bowel Dis. 2011 Dec;17(12):2536-40
pubmed: 21538710
World J Gastroenterol. 2013 Mar 7;19(9):1349-53
pubmed: 23538553
Infect Dis Clin North Am. 2001 Jun;15(2):423-32, viii
pubmed: 11447704
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
J Crohns Colitis. 2013 May;7(4):322-37
pubmed: 23395397
Am J Gastroenterol. 2006 Aug;101(8):1834-40
pubmed: 16817843
Therap Adv Gastroenterol. 2019 May 21;12:1756284819847034
pubmed: 31205485
Med Clin (Barc). 2009 Mar 14;132(9):331-5
pubmed: 19268981
BMC Gastroenterol. 2011 Jul 29;11:87
pubmed: 21798078
Inflamm Bowel Dis. 2015 Aug;21(8):1754-60
pubmed: 25985242

Auteurs

Cristina García-Serrano (C)

Catalan Health Institute (ICS), Primary Care, Lleida, Spain.
Lleida Institute for Biomedical Research (IRBLleida), Lleida, Spain.

Glòria Mirada (G)

Faculty of Nursery and Physiotherapy, University of Lleida, Lleida, Spain.
Catalan Agency of Public Health, Lleida, Spain.

Josep R Marsal (JR)

Cardiovascular Epidemiology Unit, Cardiology Department, Vall d'Hebron University Hospital, CIBERESP, Lleida, Spain.

Marta Ortega (M)

Catalan Health Institute (ICS), Primary Care, Lleida, Spain.
Research Support Unit Lleida, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Lleida, Spain.
Faculty of Medicine, University of Lleida, Lleida, Spain.
Research Group in Therapies in Primary Care (GRETAPS), Lleida, Spain.

Joaquim Sol (J)

Catalan Health Institute (ICS), Primary Care, Lleida, Spain. jsol.lleida.ics@gencat.cat.
Research Support Unit Lleida, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Lleida, Spain. jsol.lleida.ics@gencat.cat.
Metabolic Physiopathology Group, Department of Experimental Medicine, University of Lleida-IRBLleida, Lleida, Spain. jsol.lleida.ics@gencat.cat.

Rubén Solano (R)

Research Support Unit Lleida, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Lleida, Spain.

Eva M Artigues (EM)

Catalan Health Institute (ICS), Primary Care, Lleida, Spain.
Faculty of Nursery and Physiotherapy, University of Lleida, Lleida, Spain.
Research Support Unit Lleida, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Lleida, Spain.
Research Group in Therapies in Primary Care (GRETAPS), Lleida, Spain.
Research Group in Health Education (GREpS), Department of Nursery and Physiotherapy, University of Lleida, Lleida, Spain.

Pepi Estany (P)

Catalan Health Institute (ICS), Primary Care, Lleida, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH